D Medical Industries is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of products for diabetes treatment and drug delivery.
D Medical CEO Efri Argaman said as they move forward with the process of transferring the manufacturing of all of ‘Spring’ branded products to China and prepare to introduce and promote them in various target markets – including the US, Canada, Europe, Mexico and the BRIC countries of Brazil, Russia, India and China – the SEDA will provide the company with the flexibility to draw capital in an amount and at the time of their choosing.
"This will place the company in a more comfortable position for pursuing our commercial development plans and provide a safety net to mitigate any uncertainties that may occur on our way to reaching our goals," Argaman said.
Yorkville Advisors MD and Healthcare Group head Michael Nowak said they are excited to be investing in D Medical, an innovator in the insulin-delivery device market and provider in the Israeli medical device sector.
